Prostate Specific Antigen (PSA), a biochemical marker used clinically for prostate cancer detection and prognosis, is associated with substantial overdiagnosis and excessive treatment [19], which makes its utility as a screening test controversial, and warrants the need for further studies. The gene discussed is KLK3; the disease is prostate carcinoma.